glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.25700/NJG.2020.02.06glaucoma-297Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEW OF LITERATUREМаксимальная медикаментозная терапия глаукомы — что есть в нашем арсенале?Maximum medical therapy for glaucoma — what is in our arsenal?АнтоновА. А.AntonovA. A.

Антонов Алексей Анатольевич, кандидат медицинских наук, ведущий научный сотрудник отдела глаукомы

119021, Москва, ул. Россолимо, 11А.

 

Ph.D., Leading research associate of Glaucoma Department

11A Rossolimo st., Moscow, 119021

niigb.antonov@gmail.comКозловаИ. В.KozlovaI. V.

Кандидат медицинских наук, ведущий научный сотрудник отдела глаукомы

119021, Москва, ул. Россолимо, 11А.

 

Ph.D., leading research associate of Glaucoma Department

11A Rossolimo st., Moscow, 119021

ВитковА. А.VitkovA. A.

Ординатор

119021, Москва, ул. Россолимо, 11А.

Resident

11A Rossolimo st., Moscow, 119021

ФГБНУ «НИИ глазных болезней»РоссияScientific Research Institute of Eye DiseasesRussian Federation2020101020201925158Copyright © Антонов А.А., Козлова И.В., Витков А.А., 20202020Антонов А.А., Козлова И.В., Витков А.А.Antonov A.A., Kozlova I.V., Vitkov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/297

Повышенный уровень внутриглазного давления (ВГД) является единственным модифицируемым фактором риска развития и прогрессирования глаукомы. Терапия глаукомы до проведения хирургического лечения может заключаться в инстилляциях нескольких гипотензивных препаратов в течение длительного времени. Лучшие антиглаукомные средства обладают наибольшим гипотензивным эффектом при минимальной кратности закапывания. Фиксированная комбинация биматопроста и тимолола в настоящее время является наиболее эффективной среди известных препаратов. Добавление к этому режиму местных ингибиторов карбоангидразы, в частности бринзоламида, может считаться максимальной терапией глаукомы при оптимальной переносимости. В данном обзоре предпринята попытка обобщить актуальные данные о наиболее эффективных антиглаукомных средствах, в частности, о фиксированной комбинации биматопроста и тимолола, а также бринзоламиде. Помимо прочего, будет затронута тема своевременности проведения хирургического лечения на максимальном режиме.

Elevated intraocular pressure (IOP) is the only modifiable risk factor for glaucoma development and progression. Glaucoma therapy prior to surgical treatment may consist in the instillation of many hypotensive drugs for a long time. The best of them have the greatest hypotensive effect with a minimum frequency of instillation. The fixed combination of bimatoprost and timolol is currently the most effective among the known drugs. The addition of local carbonic anhydrase inhibitors, in particular, brinzolamide, to this regimen can be considered the maximum glaucoma therapy with optimal tolerance. This review will attempt to summarize relevant data on the most effective anti-glaucoma drugs, in particular, on a fixed combination of bimatoprost and timolol, and brinzolamide. Among other things, the timeliness of surgical treatment at the maximum glaucoma therapy will be investigated.

глаукомавнутриглазное давлениефиксированная комбинация биматопроста и тимололабринзоламидglaucomaintraocular pressurebimatoprost/timolol fixed combinationtimololReferencesPatel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26(3):233-236.Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26(3):233-236.Казанова С., Страхов В. Анализ темпов прогрессирования глаукомного процесса при различных вариантах несоблюдения комплаенса лечения. Национальный журнал глаукома. 2016; 15(2):74-83.Kazanova S.Y., Strakhov V.V. Analysis of glaucoma process progression rates depending on various treatment non-compliance scenarios. Natsional’nyi zhurnal glaukoma. 2016; 15(2):74-83. (In Russ.).Егоров Е., Ловпаче Д.Н., Харьковский А. Compliance. Что стоит за этим термином? РМЖ Клиническая офтальмология. 2008; 9(3):84-86.Egorov E.A., Lovpache D.N., Kharkovskiy A. Compliance in glaucoma patients. RMJ Clinical Ophthalmology. 2008; 9(3):84-86. (In Russ.).Sherwood M.B., Grierson I., Millar L., Hitchings R.A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96(3):327- 335. doi:10.1016/s0161-6420(89)32888-0Sherwood M.B., Grierson I., Millar L., Hitchings R.A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96(3):327- 335. doi:10.1016/s0161-6420(89)32888-0Hong S., Lee C.S., Seo K.Y., Seong G.J., Hong Y.J. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006; 142(1):185-186. doi:10.1016/j.ajo.2006.02.056Hong S., Lee C.S., Seo K.Y., Seong G.J., Hong Y.J. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006; 142(1):185-186. doi:10.1016/j.ajo.2006.02.056Broadway D.C., Grierson I., O'Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994; 112(11):1446-1454. doi:10.1001/archopht.1994.01090230060021Broadway D.C., Grierson I., O'Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994; 112(11):1446-1454. doi:10.1001/archopht.1994.01090230060021Куроедов А., Нагорнова З.М., Селезнев А., Завадский П., Брежнев А., Петров С. Влияние различных инстилляционных гипотензивных режимов на развитие и прогрессирование синдрома «сухого глаза». Национальный журнал глаукома. 2017; 16(3):71-80.Kuroyedov A.V., Nagornova Z.M., Seleznev A.V., Zavadskiy P.C., Brezhnev A.Y., Petrov S.Y. Influence of different local hypotensive therapy regimens on the development and progression of the «dry eye» syndrome. Natsional’nyi zhurnal glaukoma. 2017; 16(3):71-80. (In Russ.).Еричев В., Амбарцумян К.Г., Федоров А. Клинико-морфологические доказательства влияния консервантов на поверхность глаза при первичной открытоугольной глаукоме. Национальный журнал глаукома. 2014; 13(4):13-22.Erichev V.P., Ambartsumyan K.H., Fedorov A.A. Clinical and morphological evidence of the effect of preservatives on the eye surface in primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2014;13(4):13-22. (In Russ.).Нагорнова З.М., Куроедов А.В., Петров С.Ю., Селезнев А., Газизова И., Павлова Л. Влияние местной гипотензивной терапии на состояние тканей глазной поверхности и исход антиглаукомных операций у пациентов с первичной открытоугольной глаукомой. Национальный журнал глаукома. 2019; 18(4):96-107.Nagornova Z.M., Kuroyedov A.V., Petrov S.Y., Seleznev A.V., Gazizova I.R., Pavlova L.S. The effect of topical hypotensive therapy on ocular surface and glaucoma surgery outcomes in patients with primary openangle glaucoma. Natsional’nyi zhurnal glaukoma. 2019; 18(4):96-107. (In Russ.). https://doi.org/10.25700/NJG.2019.04.08Van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7):1177-1185. doi:10.1016/j.ophtha.2005.01.042Van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7):1177-1185. doi:10.1016/j.ophtha.2005.01.042Li T., Lindsley K., Rouse B., Hong H., Shi Q., Friedman D.S., Wormald R., Dickersin K. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network metaanalysis. Ophthalmology. 2016; 123(1):129-140. doi:10.1016/j.ophtha.2015.09.005Li T., Lindsley K., Rouse B., Hong H., Shi Q., Friedman D.S., Wormald R., Dickersin K. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network metaanalysis. Ophthalmology. 2016; 123(1):129-140. doi:10.1016/j.ophtha.2015.09.005Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008; 17(8):667-673. doi:10.1097/IJG.0b013e3181666557Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008; 17(8):667-673. doi:10.1097/IJG.0b013e3181666557Экгардт В., Дорофеев Д.А. Возможности стартовой терапии простой и псевдоэксфолиативной открытоугольной глаукомы аналогами простагландинов при продвинутых стадиях заболевания. Национальный журнал глаукома. 2017; 16(1):29-37.Ekgardt V.F., Dorofeev D.A. Effects of prostaglandin analogues initial treatment on simple open-angle glaucoma and pseudoexfoliation glaucoma in advance stages. Natsional’nyi zhurnal glaukoma. 2017; 16(1):29-37. (In Russ.).European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition. Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017; 101(6):130-195. doi:10.1136/bjophthalmol-2016-EGSguideline.003European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition. Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017; 101(6):130-195. doi:10.1136/bjophthalmol-2016-EGSguideline.003Woodward D.F., Krauss A.H., Chen J., Liang Y., Li C., Protzman C.E., Bogardus A., Chen R., Kedzie K.M., Krauss H.A., Gil D.W., Kharlamb A., Wheeler L.A., Babusis D., Welty D., Tang-Liu D.D., Cherukury M., Andrews S.W., Burk R.M., Garst M.E. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003; 305(2):772-785. doi:10.1124/jpet.102.047837Woodward D.F., Krauss A.H., Chen J., Liang Y., Li C., Protzman C.E., Bogardus A., Chen R., Kedzie K.M., Krauss H.A., Gil D.W., Kharlamb A., Wheeler L.A., Babusis D., Welty D., Tang-Liu D.D., Cherukury M., Andrews S.W., Burk R.M., Garst M.E. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003; 305(2):772-785. doi:10.1124/jpet.102.047837Brubaker R.F., Schoff E.O., Nau C.B., Carpenter S.P., Chen K., Vandenburgh A.M. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001; 131(1):19-24. doi:10.1016/s0002-9394(00)00843-6Brubaker R.F., Schoff E.O., Nau C.B., Carpenter S.P., Chen K., Vandenburgh A.M. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001; 131(1):19-24. doi:10.1016/s0002-9394(00)00843-6Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M., Andrews S.W., Shi L., Liang Y., Kedzie K.M., Chen R., Gil D.W., Kharlamb A., Archeampong A., Ling J., Madhu C., Ni J., Rix P., Usansky J., Usansky H., Weber A., Welty D., Yang W., Tang-Liu D.D., Garst M.E., Brar B., Wheeler L.A., Kaplan L.J. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001; 45 Suppl 4:S337-345. doi:10.1016/s0039-6257(01)00224-7Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M., Andrews S.W., Shi L., Liang Y., Kedzie K.M., Chen R., Gil D.W., Kharlamb A., Archeampong A., Ling J., Madhu C., Ni J., Rix P., Usansky J., Usansky H., Weber A., Welty D., Yang W., Tang-Liu D.D., Garst M.E., Brar B., Wheeler L.A., Kaplan L.J. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001; 45 Suppl 4:S337-345. doi:10.1016/s0039-6257(01)00224-7Holmstrom S., Buchholz P., Walt J., Wickstrom J., Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005; 21(11):1875-1883. doi:10.1185/030079905X65600Holmstrom S., Buchholz P., Walt J., Wickstrom J., Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005; 21(11):1875-1883. doi:10.1185/030079905X65600Rossetti L., Karabatsas C.H., Topouzis F., Vetrugno M., Centofanti M., Boehm A., Viswanathan A., Vorwerk C., Goldblum D. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology. 2007; 114(12):2244-2251. doi:10.1016/j.ophtha.2007.01.025Rossetti L., Karabatsas C.H., Topouzis F., Vetrugno M., Centofanti M., Boehm A., Viswanathan A., Vorwerk C., Goldblum D. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology. 2007; 114(12):2244-2251. doi:10.1016/j.ophtha.2007.01.025Kiland J.A., Gabelt B.T., Kaufman P.L. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004; 78(3):639-651. doi:10.1016/j.exer.2003.11.001Kiland J.A., Gabelt B.T., Kaufman P.L. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004; 78(3):639-651. doi:10.1016/j.exer.2003.11.001Amyot M., Blondeau P. [Timolol maleate. Pharmacology and review of the literature]. Can J Ophthalmol. 1979; 14(3):208-214.Amyot M., Blondeau P. [Timolol maleate. Pharmacology and review of the literature]. Can J Ophthalmol. 1979; 14(3):208-214.Piltz J., Gross R., Shin D.H., Beiser J.A., Dorr D.A., Kass M.A., Gordon M.O. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol. 2000; 130(4):441-453. doi:10.1016/s0002-9394(00)00527-4Piltz J., Gross R., Shin D.H., Beiser J.A., Dorr D.A., Kass M.A., Gordon M.O. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol. 2000; 130(4):441-453. doi:10.1016/s0002-9394(00)00527-4Aptel F., Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011; 27(10):1949-1958. doi:10.1185/03007995.2011.613923Aptel F., Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011; 27(10):1949-1958. doi:10.1185/03007995.2011.613923Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86(4):418-423. doi:10.1136/bjo.86.4.418Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86(4):418-423. doi:10.1136/bjo.86.4.418Chrai S.S., Makoid M.C., Eriksen S.P., Robinson J.R. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974; 63(3):333-338. doi:10.1002/jps.2600630304Chrai S.S., Makoid M.C., Eriksen S.P., Robinson J.R. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974; 63(3):333-338. doi:10.1002/jps.2600630304Liu A.W., Gan L.Y., Yao X., Zhou J. Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. Int J Ophthalmol. 2016; 9(5):750-756. doi:10.18240/ijo.2016.05.21Liu A.W., Gan L.Y., Yao X., Zhou J. Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. Int J Ophthalmol. 2016; 9(5):750-756. doi:10.18240/ijo.2016.05.21Brandt J.D., Cantor L.B., Katz L.J., Batoosingh A.L., Chou C., Bossowska I., Ganfort Investigators G, II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008; 17(3):211-216. doi:10.1097/IJG.0b013e3181507313Brandt J.D., Cantor L.B., Katz L.J., Batoosingh A.L., Chou C., Bossowska I., Ganfort Investigators G, II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008; 17(3):211-216. doi:10.1097/IJG.0b013e3181507313DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000; 44 Suppl 2:S119-129. doi:10.1016/s0039-6257(99)00108-3DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000; 44 Suppl 2:S119-129. doi:10.1016/s0039-6257(99)00108-3Wistrand P.J., Garg L.C. Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci. 1979; 18(8):802-806.Wistrand P.J., Garg L.C. Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci. 1979; 18(8):802-806.Ingram C.J., Brubaker R.F. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999; 128(3):292-296. doi:10.1016/s0002-9394(99)00179-8Ingram C.J., Brubaker R.F. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999; 128(3):292-296. doi:10.1016/s0002-9394(99)00179-8Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012; 22(1):5-18. doi:10.5301/ejo.5000009Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012; 22(1):5-18. doi:10.5301/ejo.5000009Lou H., Wang H., Zong Y., Cheng J.W., Wei R.L. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015; 31(6):1139-1147. doi:10.1185/03007995.2015.1039504Lou H., Wang H., Zong Y., Cheng J.W., Wei R.L. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015; 31(6):1139-1147. doi:10.1185/03007995.2015.1039504Cheng J.W., Cheng S.W., Gao L.D., Lu G.C., Wei R.L. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9):e45079. doi:10.1371/journal.pone.0045079Cheng J.W., Cheng S.W., Gao L.D., Lu G.C., Wei R.L. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9):e45079. doi:10.1371/journal.pone.0045079Konstas A.G., Hollo G., Mikropoulos D., Tsironi S., Haidich A.B., Embeslidis T., Georgiadou I., Irkec M., Melamed S. Twenty-fourhour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010; 94(2):209-213. doi:10.1136/bjo.2008.155317Konstas A.G., Hollo G., Mikropoulos D., Tsironi S., Haidich A.B., Embeslidis T., Georgiadou I., Irkec M., Melamed S. Twenty-fourhour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010; 94(2):209-213. doi:10.1136/bjo.2008.155317Shim S.H., Kim J.M., Choi C.Y., Kim C.Y. Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects. Korean J Ophthalmol. 2014; 28(1):39-48. doi:10.3341/kjo.2014.28.1.39Shim S.H., Kim J.M., Choi C.Y., Kim C.Y. Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects. Korean J Ophthalmol. 2014; 28(1):39-48. doi:10.3341/kjo.2014.28.1.39Guven Yilmaz S., Degirmenci C., Karakoyun Y.E., Yusifov E., Ates H. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/ timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018; 38(4):1425-1431. doi:10.1007/s10792-017-0601-8Guven Yilmaz S., Degirmenci C., Karakoyun Y.E., Yusifov E., Ates H. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/ timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018; 38(4):1425-1431. doi:10.1007/s10792-017-0601-8Centofanti M., Oddone F., Vetrugno M., Manni G., Fogagnolo P., Tanga L., Ferreri P., Rossetti L. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19(1):66-71. doi:10.1177/112067210901900110Centofanti M., Oddone F., Vetrugno M., Manni G., Fogagnolo P., Tanga L., Ferreri P., Rossetti L. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19(1):66-71. doi:10.1177/112067210901900110Martinez A., Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23(5):1025-1032. doi:10.1185/030079907x182149Martinez A., Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23(5):1025-1032. doi:10.1185/030079907x182149Martinez A., Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23(4):810-818. doi:10.1038/eye.2008.148Martinez A., Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23(4):810-818. doi:10.1038/eye.2008.148Centofanti M., Oddone F., Gandolfi S., Hommer A., Boehm A., Tanga L., Sangermani C., Sportelli V., Haustein M., Manni G., Rossetti L. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol. 2010; 150(4):575-580. doi:10.1016/j.ajo.2010.05.003Centofanti M., Oddone F., Gandolfi S., Hommer A., Boehm A., Tanga L., Sangermani C., Sportelli V., Haustein M., Manni G., Rossetti L. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol. 2010; 150(4):575-580. doi:10.1016/j.ajo.2010.05.003Lee M.Y., Teh N.C., Nur Zulekha M., Thayanithi S., Jelinar M.N., Rizal A.M., Arfah W. The effects of fixed combination of bimatoprost-timolol and travoprost-timolol on intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension, previously on nonfixed combination of latanoprost and timolol. Asia Pac J Ophthalmol (Phila). 2012; 1(4):208-212. doi:10.1097/APO.0b013e31825c5b1bLee M.Y., Teh N.C., Nur Zulekha M., Thayanithi S., Jelinar M.N., Rizal A.M., Arfah W. The effects of fixed combination of bimatoprost-timolol and travoprost-timolol on intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension, previously on nonfixed combination of latanoprost and timolol. Asia Pac J Ophthalmol (Phila). 2012; 1(4):208-212. doi:10.1097/APO.0b013e31825c5b1bGarcia-Lopez A., Paczka J.A., Jimenez-Roman J., Hartleben C. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol. 2014; 14:161. doi:10.1186/1471-2415-14-161Garcia-Lopez A., Paczka J.A., Jimenez-Roman J., Hartleben C. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol. 2014; 14:161. doi:10.1186/1471-2415-14-161Jothi R., Ismail A.M., Senthamarai R., Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol. 2010; 42(6):362-365. doi:10.4103/0253-7613.71917Jothi R., Ismail A.M., Senthamarai R., Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol. 2010; 42(6):362-365. doi:10.4103/0253-7613.71917Sacchi M., Specchia C., Williams S.E., Villani E., Nucci P. Efficacy of bimatoprost plus timolol fixed combination in open angle glaucoma patients previously treated with dorzolamide plus timolol fixed combination. Curr Eye Res. 2016; 41(11):1433-1437. doi:10.3109/027136 83.2015.1125507Sacchi M., Specchia C., Williams S.E., Villani E., Nucci P. Efficacy of bimatoprost plus timolol fixed combination in open angle glaucoma patients previously treated with dorzolamide plus timolol fixed combination. Curr Eye Res. 2016; 41(11):1433-1437. doi:10.3109/027136 83.2015.1125507Goldberg I., Crowston J.G., Jasek M.C., Stewart J.A., Stewart W.C., Group ASI. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma. 2012; 21(1):55-59. doi:10.1097/IJG.0b013e3181fc8142Goldberg I., Crowston J.G., Jasek M.C., Stewart J.A., Stewart W.C., Group ASI. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma. 2012; 21(1):55-59. doi:10.1097/IJG.0b013e3181fc8142Tsukamoto H., Noma H., Matsuyama S., Ikeda H., Mishima H.K. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther. 2005; 21(2):170-173. doi:10.1089/jop.2005.21.170Tsukamoto H., Noma H., Matsuyama S., Ikeda H., Mishima H.K. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther. 2005; 21(2):170-173. doi:10.1089/jop.2005.21.170Pfeiffer N., group T. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2011; 249(7):1065-1071. doi:10.1007/s00417-011-1650-8Pfeiffer N., group T. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2011; 249(7):1065-1071. doi:10.1007/s00417-011-1650-8

The authors declare that there are no conflicts of interest present.